Key points Obesity is a risk factor for developing osteoarthritis (OA), gout, rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), and is associated with higher disease activity and/or severity, and worse response to common treatments
Patients tracking their results on semaglutide should know that color changes during a treatment cycle can explain unexpected plateaus or lack of weight loss , because degraded medication simply does not work as intended
It can lower your risk of developing fine lines and wrinkles
The optional Precision Peptide Genetic Test ($99 after month one) provides personalized insights into your peptide-pathway genetics, helping optimize your semaglutide dose and minimize side effects that could complicate anticoagulation management
Individual results depend on factors including starting weight, dose, lifestyle changes, and adherence to treatment